CatalYm GmbH is a clinical-stage biotechnology company dedicated to advancing cancer treatment through pioneering Visugromab, a recombinant antibody targeting the immunosuppressive cytokine GDF-15. Under physiological conditions, GDF-15 is essential in feto-maternal tolerance and protection of injured tissues. In cancer, GDF-15 is markedly overexpressed across various tumor types, hindering the body’s ability to mount effective immune […]